Avalo Therapeutics AVTX Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilitiesNet.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's deferred tax assets?
- Avalo Therapeutics (AVTX) reported deferred tax assets of $446K in Q1 2026.
- How has Avalo Therapeutics's deferred tax assets changed year-over-year?
- Avalo Therapeutics's deferred tax assets increased by 60.4% year-over-year, from $278K to $446K.
- What is the long-term trend for Avalo Therapeutics's deferred tax assets?
- Over 5 years (2020 to 2025), Avalo Therapeutics's deferred tax assets has grown at a 37.0% compound annual growth rate (CAGR), from $90K to $434K.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.